A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel for Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine
Latest Information Update: 05 Dec 2022
At a glance
- Drugs Iparomlimab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 24 Jun 2020 New trial record